Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date.
about
Nanomedicine-Mediated Therapies to Target Breast Cancer Stem CellsTransmission electron microscopy for nanomedicine: novel applications for long-established techniquesCurrent Multistage Drug Delivery Systems Based on the Tumor Microenvironment.In Vitro Neurotoxicity Resulting from Exposure of Cultured Neural Cells to Several Types of Nanoparticles.The era of bioengineering: how will this affect the next generation of cancer immunotherapy?Advanced Analgesic Drug Delivery and Nanobiotechnology.Vascular mineralocorticoid receptor regulates microRNA-155 to promote vasoconstriction and rising blood pressure with aging.Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics.Mesoporous Silica Nanoparticles as Drug Delivery Vehicles in Cancer.Molecular Imaging in Nanotechnology and Theranostics.Strategies for improving drug delivery: nanocarriers and microenvironmental priming.Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures.Energy-triggered drug release from polymer nanoparticles for orthopedic applications.Advances in the clinical translation of nanotechnology.Biomimetic and bioinspired nanoparticles for targeted drug delivery.Targeting and delivery of therapeutic enzymes.Could targeted, antibiotic-loaded gold nanoconstructs be a new magic bullet to fight infection?Gold nanoparticles partition to and increase the activity of glucose-6-phosphatase in a synthetic phospholipid membrane system.Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells.An annotated corpus with nanomedicine and pharmacokinetic parameters.Thermoresponsive pegylated bubble liposome nanovectors for efficient siRNA delivery via endosomal escape.A Near-Infrared Responsive Drug Sequential Release System for Better Eradicating Amyloid Aggregates.Equivalence of complex drug products: advances in and challenges for current regulatory frameworks.The potential of multi-compound nanoparticles to bypass drug resistance in cancer.Personalized Nanomedicine: A Revolution at the Nanoscale.Recent advancements in biocompatible inorganic nanoparticles towards biomedical applications.Covalent Organic Frameworks: From Materials Design to Biomedical Application.Mesoporous Silica and Organosilica Nanoparticles: Physical Chemistry, Biosafety, Delivery Strategies, and Biomedical Applications.Exploiting homing abilities of cell carriers: Targeted delivery of nanoparticles for cancer therapy.Expanding Analytical Tools for Characterizing Ultrasmall Silica-based Nanoparticles.Camptothecin-based nanodrug delivery systems.Utility of PEGylated dithiolane ligands for direct synthesis of water-soluble Au, Ag, Pt, Pd, Cu and AuPt nanoparticles.Recent Advances in the Generation of Antibody-Nanomaterial Conjugates.Anti-inflammatory Nanomedicine for Cardiovascular Disease.Robust manufacturing of lipid-polymer nanoparticles through feedback control of parallelized swirling microvortices.In Vivo Biosensing: Progress and Perspectives.Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy.Promising effects of nanomedicine in cancer drug delivery.The Use of Liposomes and Nanoparticles as Drug Delivery Systems to Improve Cancer Treatment in Dogs and Cats.Liposome-encapsulated chemotherapy: Current evidence for its use in companion animals.
P2860
Q28066297-DE60A408-8F07-4E8E-939B-BB7CAFBA9640Q28818768-E0AD31E8-0B1D-4D2F-A26C-A286D030247EQ30362001-6D716E43-C647-476C-88F6-F5B62BD757F2Q33565973-C2189C5E-724B-4E74-80B6-445B6BE48756Q33815087-C60FCB7D-125C-45C4-AD0A-D307976AB6E2Q33845298-84136D78-094E-4A69-8114-1A5DCEACD5FFQ37277242-42434EAC-9644-4728-99F4-AEC055B5688CQ38557048-D9052573-ED96-49B2-A0D8-B91FC6F6F05EQ38665073-38920CE9-47BA-42C2-AC2F-8E38A098DA5FQ38738754-65EB609F-1DC8-4E15-A397-2D2239298B4FQ38968910-A42E07A7-107F-4258-8EDF-B4C205544359Q38978632-F49EF82A-528C-4C9B-A9F8-AD3C1BB4B91DQ39041192-2143AF2E-EA13-4A8D-AB32-97E240FBEAD0Q39130471-63AB9821-BFBE-451D-AF22-0BB08D1E21B9Q39210548-CAA1BC86-AA25-4C17-A49F-7153D670DE5CQ39386527-86E62F87-4F49-4838-A8BE-90C0DCDF8EC3Q40574073-0CE7622D-8A0F-4657-9DB8-AB568E174A6CQ41443683-65694611-3CFF-447C-8E6D-E262513B4045Q42335714-7F760899-2FBE-4A7C-A359-42F86863D6B0Q42656502-A57F09DE-41F1-4228-B7C6-6A313ACF129DQ45867909-C4BEBF34-E59B-4F57-B4B1-EBE27D8F4ACAQ46287826-40DAC938-FCB2-4AAE-AE3A-ED629E8451C4Q46611022-3BFE0E06-1F1C-4190-B843-4363548D6DBFQ47114290-D49FC756-E2F9-41B6-BA80-6C7C28E05559Q47159637-0CBCDCB5-93EF-4F63-928B-319C7EEAC3CCQ47195292-B1FD16C1-4675-404C-B462-A2F4D71B2207Q47214325-71A8D658-7467-46D0-B8A1-DCE509FDB86BQ47295411-44F821AC-DE97-48F1-8ADB-32D97E67EA0BQ47568478-CF2A88D0-AA37-40FC-BC94-A74B0E2A23DCQ47638586-99907D85-7BC8-4063-9042-F82AC636995AQ47700115-1FC9AA6E-2855-4B8B-B402-EAB791742749Q47723502-770DAD89-52D1-4CFC-B0E4-4347F94359E2Q47725919-36E60F09-DB1C-4117-84EB-6C630F5EE5BCQ47744781-1D57C439-E789-4EDC-AEC6-8E89298497F4Q47903206-C70ECA4C-30E7-4624-96B0-036089DA095FQ47907365-DC2B0EC7-C13B-4DAB-95D2-23A363D5F783Q47962563-16069FB3-009B-475A-8F7F-F442FC782F15Q48122525-0AD12425-60B5-41CD-8C3C-5BAD05307C4FQ48160138-F1C77F1A-F0C8-4802-9BC7-82BB5742C1BAQ48192967-517550A3-92B8-4DD6-908B-26B12E0D7C35
P2860
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Nanoparticle-Based Medicines: ...... s and Clinical Trials to Date.
@en
type
label
Nanoparticle-Based Medicines: ...... s and Clinical Trials to Date.
@en
prefLabel
Nanoparticle-Based Medicines: ...... s and Clinical Trials to Date.
@en
P2093
P2860
P1476
Nanoparticle-Based Medicines: ...... s and Clinical Trials to Date.
@en
P2093
Jiaul Islam
Kristofer J Thurecht
Kye J Robinson
P2860
P304
P356
10.1007/S11095-016-1958-5
P577
2016-06-14T00:00:00Z